BioSpace News Archive

Windtree Therapeutics, Inc. reported that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for istaroxime administration.

Immutep Limited, a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 September 2022.

Recursion announced that it has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement, led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management.

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial.

Thorne HealthTech, Inc. (“Thorne HealthTech” or “Thorne”) (NASDAQ: THRN) announced today that it is collaborating with GenTegra to utilize GenTegra’s patented Active Chemical Protection™ technology and Thorne’s OneDraw™ collection device to develop a whole blood DNA collection cartridge and a complete stabilization and extraction kit.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2022 financial results will be released after the market close on November 8, 2022 .

Tenon Medical, Inc. today announced Institutional Review Board (“IRB”) approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of the Company’s Catamaran SI Joint Fusion System (the “Catamaran”).

Aytu BioPharma, Inc. today announced an agreement with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”) to extend the interest-only period of the Company’s existing senior secured loan facility held with Avenue.

EndoStim, a medical device company developing and commercializing a first-in-class implantable neurostimulation treatment for drug refractory gastroesophageal reflux disease (GERD), announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System.

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer.